Transfusion Medicine Reviews
Volume 24, Issue 1 , Pages 44-52 , January 2010

Correction of Coagulation in Dilutional Coagulopathy: Use of Kinetic and Capacitive Coagulation Assays to Improve Hemostasis

  • Saskia E.M. Schols
    • ,
  • Johan W.M. Heemskerk

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Johan W.M. Heemskerk, Department of Biochemistry (CARIM), Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
    • Authors contributed equally to this paper.
    • ,
  • Elisabeth C.M. van Pampus

      Affiliations

    • Authors contributed equally to this paper.

References 

  1. Levy JH. Massive transfusion coagulopathy. Semin Hematol. 2006;43:S59–S63
  2. Stainsby D, MacLennan S, Thomas D, et al. Guidelines on the management of massive blood loss. Br J Haematol. 2006;135:634–641
  3. Hellstern P, Muntean W, Schramm W, et al. Practical guidelines for the clinical use of plasma. Thromb Res. 2002;107:S53–S57
  4. Hellstern P, Haubelt H. Indications for plasma in massive transfusion. Thromb Res. 2002;107:S19–S22
  5. Hardy JF, de Moerloose P, Samama CM. Massive transfusion and coagulopathy: Pathophysiology and implications for clinical management. Can J Anaesth. 2006;53:S40–S58
  6. Hardy JF, de Moerloose P, Samama CM. The coagulopathy of massive transfusion. Vox Sang. 2005;89:123–127
  7. Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiol. 2007;73:401–415
  8. American-Society-of-Anesthesiologists. Practice guidelines for blood component therapy. Anesthesiology. 1996;84:732–747
  9. Samama CM, Djoudi R, Lecompte T, et al. Perioperative platelet transfusion. Recommendations of the French Health Products Safety Agency (AFSSAPS) 2003. Minerva Anestesiol. 2006;72:447–452
  10. Heindl B, Biberthaler P. Coagulation management of severe surgical bleeding. Unfallchirurg. 2008;111:574–583
  11. Erber WN. Massive blood transfusion in the elective surgical setting. Transfus Apher Sci. 2002;27:83–92
  12. Gaarder C, Naess PA, Frischknecht Christensen E, et al. Scandinavian Guidelines-The massively bleeding patient. Scand J Surg. 2008;97:15–36
  13. Spahn DR, Cerny V, Coats TJ, et al. Management of bleeding following major trauma: A European guideline. Crit Care. 2007;11:R17
  14. Mitra B, Mori A, Cameron PA, et al. Massive blood transfusion and trauma resuscitation. Injury. 2007;38:1023–1029
  15. Malone DL, Hess JR, Fingerhut A, et al. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma. 2006;60:S91–S96
  16. O'Keeffe T, Refaai M, Tchorz K, et al. A massive transfusion protocol to decrease blood component use and costs. Arch Surg. 2008;143:686–690
  17. Ketchum L, Hess JR, Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. J Trauma. 2006;60:S51–S58
  18. Spivey M, Parr MJ. Therapeutic approaches in trauma-induced coagulopathy. Minerva Anestesiol. 2005;71:281–289
  19. Perkins JG, Cap AP, Weiss BM, et al. Massive transfusion and nonsurgical hemostatic agents. Crit Care Med. 2008;36:S325–S339
  20. Busani S, Cavazzuti I, Marietta M, et al. Strategies to control massive abdominal bleeding. Transplant Proc. 2008;40:1212–1215
  21. Grottke O, Henzler D, Rossaint R. Use of blood and blood products in trauma. Best Pract Res Clin Anaesthesiol. 2007;21:257–270
  22. Hakala P, Hiippala S, Syrjala M, et al. Massive blood transfusion exceeding 50 units of plasma poor red cells or whole blood: The survival rate and the occurrence of leukopenia and acidosis. Injury. 1999;30:619–622
  23. Kashuk JL, Moore EE, Johnson JL, et al. Postinjury life threatening coagulopathy: Is 1:1 fresh frozen plasma:packed red blood cells the answer?. J Trauma. 2008;65:261–270
  24. Spinella PC. Warm fresh whole blood transfusion for severe hemorrhage: U.S. military and potential civilian applications. Crit Care Med. 2008;36:S340–S345
  25. Schreiber MA, Perkins J, Kiraly L, et al. Early predictors of massive transfusion in combat casualties. J Am Coll Surg. 2007;205:541–545
  26. Hess JR, Holcomb JB. Transfusion practice in military trauma. Transfus Med. 2008;18:143–150
  27. Singbartl K, Innerhofer P, Radvan J, et al. Hemostasis and hemodilution: A quantitative mathematical guide for clinical practice. Anesth Analg. 2003;96:929–935
  28. Karlsson M, Ternstrom L, Hyllner M, et al. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: A prospective observational study. Transfusion. 2008;48:2152–2158
  29. Mangus RS, Kinsella SB, Nobari MM, et al. Predictors of blood product use in orthotopic liver transplantation using the piggyback hepatectomy technique. Transplant Proc. 2007;39:3207–3213
  30. Valeri CR, Ragno G, Pivacek LE, et al. A multicenter study of in vitro and in vivo values in human RBCs frozen with 40-percent (wt/vol) glycerol and stored after deglycerolization for 15 days at 4 degrees C in AS-3: Assessment of RBC processing in the ACP 215. Transfusion. 2001;41:933–939
  31. Hirshberg A, Dugas M, Banez EI, et al. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: A computer simulation. J Trauma. 2003;54:454–463
  32. Moore FA, Nelson T, McKinley BA, et al. Is there a role for aggressive use of fresh frozen plasma in massive transfusion of civilian trauma patients?. Am J Surg. 2008;196:948–958
  33. Scalea TM, Bochicchio KM, Lumpkins K, et al. Early aggressive use of fresh frozen plasma does not improve outcome in critically injured trauma patients. Ann Surg. 2008;248:578–584
  34. Stinger HK, Spinella PC, Perkins JG, et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma. 2008;64:S79–S85
  35. Despotis G, Eby C, Lublin DM. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion. 2008;48:2S–30S
  36. Hemker HC, Al Dieri R, De Smedt E, et al. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96:553–561
  37. Vanschoonbeek K, Feijge MA, Van Kampen RJ, et al. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: Subject-dependent variation in thrombogram characteristics. J Thromb Haemost. 2004;2:476–484
  38. Haas T, Fries D, Velik-Salchner C, et al. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution. Anesth Analg. 2008;106:1360–1365
  39. Schols SE, Feijge MA, Lance MD, et al. Effects of plasma dilution on tissue factor-induced thrombin generation and thromboelastography: Partly compensating role of platelets. Transfusion. 2008;2384–2394
  40. Tanaka KA, Taketomi T, Szlam F, et al. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Anesth Analg. 2008;106:732–738
  41. Ganter MT, Schmuck S, Hamiel CR, et al. Monitoring recombinant factor VIIa treatment: Efficacy depends on high levels of fibrinogen in a model of severe dilutional coagulopathy. J Cardiothorac Vasc Anesth. 2008;22:675–680
  42. Johansson PI, Jacobsen N, Viuff D, et al. Differential clot stabilising effects of rFVIIa and rFXIII-A2 in whole blood from thrombocytopenic patients and healthy volunteers. Br J Haematol. 2008;143:559–569
  43. De Lorenzo C, Calatzis A, Welsch U, et al. Fibrinogen concentrate reverses dilutional coagulopathy induced in vitro by saline but not by hydroxyethyl starch 6%. Anesth Analg. 2006;102:1194–1200
  44. Johansson PI. Off-label use of recombinant factor VIIa for treatment of haemorrhage: Results from randomized clinical trials. Vox Sang. 2008;95:1–7
  45. Goodnough LT, Shander AS. Recombinant factor VIIa: Safety and efficacy. Curr Opin Hematol. 2007;14:504–509
  46. Karkouti K, Beattie WS, Arellano R, et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation. 2008;118:331–338
  47. MacLaren R, Weber LA, Brake H, et al. A multicenter assessment of recombinant factor VIIa off-label usage: Clinical experiences and associated outcomes. Transfusion. 2005;45:1434–1442
  48. Masud F, Bostan F, Chi E, et al. Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: A retrospective analysis of dosing, efficacy, and safety outcomes. J Cardiothorac Vasc Anesth. 2008;28–33
  49. Reinhofer M, Brauer M, Franke U, et al. The value of rotation thromboelastometry to monitor disturbed perioperative haemostasis and bleeding risk in patients with cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2008;19:212–219
  50. Mengistu AM, Wolf MW, Boldt J, et al. Evaluation of a new platelet function analyzer in cardiac surgery: A comparison of modified thromboelastography and whole-blood aggregometry. J Cardiothorac Vasc Anesth. 2008;22:40–46
  51. Schols SE, van der Meijden PE, van Oerle R, et al. Increased thrombin generation and fibrinogen level after therapeutic plasma transfusion: Relation to bleeding. Thromb Haemost. 2008;99:64–70
  52. Cammerer U, Dietrich W, Rampf T, et al. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg. 2003;96:51–57
  53. Rizoli SB, Boffard KD, Riou B, et al. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: Subgroup analysis from two randomized trials. Crit Care. 2006;10:R178
  54. Zaaroor M, Soustiel JF, Brenner B, et al. Administration off label of recombinant factor-VIIa (rFVIIa) to patients with blunt or penetrating brain injury without coagulopathy. Acta Neurochir (Wien). 2008;150:663–668
  55. Stein DM, Dutton RP, Hess JR, et al. Low-dose recombinant factor VIIa for trauma patients with coagulopathy. Injury. 2008;39:1054–1061
  56. Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: Experience in a large tertiary hospital. Crit Care. 2008;12:R105
  57. Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: A prospective multinational clinical trial. J Thromb Haemost. 2008;6:622–631
  58. Yasaka M, Sakata T, Naritomi H, et al. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res. 2005;115:455–459
  59. Mittermayr M, Streif W, Haas T, et al. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: The role of fibrinogen administration. Anesth Analg. 2007;105:905–917
  60. Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfus Med. 2008;18:151–157
  61. Fenger-Eriksen C, Midtgaard Jensen T, Kristensen BS, et al. Fibrinogen substitution improves whole blood clot firmness following dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy—A randomised placebo-controlled clinical trial. J Thromb Haemost. 2009;7:795–802
  62. Danes AF, Cuenca LG, Bueno SR, et al. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang. 2008;94:221–226
  63. Fishman PE, Drumheller BC, Dubon ME, et al. Recombinant activated factor VII use in the emergency department. Emerg Med J. 2008;25:625–630
  64. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia. 1998;4:790–798
  65. Hardy JF, Belisle S, Van der Linden P. Efficacy and safety of recombinant activated factor VII to control bleeding in nonhemophiliac patients: A review of 17 randomized controlled trials. Ann Thorac Surg. 2008;86:1038–1048
  66. Moltzan CJ, Anderson DA, Callum J, et al. The evidence for the use of recombinant factor VIIa in massive bleeding: Development of a transfusion policy framework. Transfus Med. 2008;18:112–120
  67. Samama CM. Prothrombin complex concentrates: A brief review. Eur J Anaesthesiol. 2008;25:784–789
  68. Haas T, Fries D, Velik-Salchner C, et al. Fibrinogen in craniosynostosis surgery. Anesth Analg. 2008;106:725–731
  69. Weisel JW. Structure of fibrin: Impact on clot stability. J Thromb Haemost. 2007;5:S116–S124
  70. van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: Are we there yet?. Br J Haematol. 2008;142:889–903
  71. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg. 2008;106:1366–1375
  72. Rugeri L, Levrat A, David JS, et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost. 2007;5:289–295
  73. Spalding GJ, Hartrumpf M, Sierig T, et al. Cost reduction of perioperative coagulation management in cardiac surgery: Value of “bedside” thrombelastography (ROTEM). Eur J Cardiothorac Surg. 2007;31:1052–1057

PII: S0887-7963(09)00084-4

doi: 10.1016/j.tmrv.2009.09.004

Transfusion Medicine Reviews
Volume 24, Issue 1 , Pages 44-52 , January 2010

Article Tools

* Image Usage & Resolution